Clinical observation on the treatment of neovascular glaucoma with intravitreal Ranibizumab injection combined with vitrectomy, panretinal photocoagulation and trabeculectomy / 国际眼科杂志(Guoji Yanke Zazhi)

ABSTRACT

@#AIM: To observe the clinical effect of ranibizumab injection combined with vitrectomy,panretinal photocoagulation(PRP)and trabeculectomy in the treatment of neovascular glaucoma(NVG).<p>METHODS: Retrospective study. From March 2017 to October 2018, 44 NVG patients(44 eyes)were treated, 22 patients(22 eyes)were treated with intravitreal injection of ranibizumab + vitrectomy + PRP+trabeculectomy(group A), and 22 patients(22 eyes)were treated with intravitreal injection of ranibizumab + trabeculectomy+PRP(group B).The patients were followed up for 6mo, the visual acuity, intraocular pressure(IOP), IOP control rate, neovascularization and complications were observed. <p>RESULTS: There was no significant difference in IOP between the two groups before treatment(46.2±9.41mmHg <i>vs</i> 49.1±10.15mmHg, <i>P</i>>0.05). The IOP of group A was lower than that of group B at 1wk, 1mo and 6mo after treatment(<i>P</i><0.05). 6mo after treatment, the visual acuity, IOP control rate(95%)and neovascularization regression(91%)in group A were better than those in group B(<i>P</i><0.05), but there was no difference in the incidence of complications between the two groups during the follow-up period(<i>P</i>>0.05).<p>CONCLUSION: It is safe and effective to treat NVG with intravitreal ranibizumab injection combined with vitrectomy, PRP and trabeculectomy, which can control IOP steadily and improve visual acuity of some patients.